NCT04541433View on ClinicalTrials.gov

A Phase 1 Study of AZD9833 in Japanese Women With ER Positive, HER2 Negative Advanced Breast Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

September 29, 2020

Primary Completion Date

July 29, 2022

Study Completion Date

June 23, 2025

Conditions
ER+ HER2- Advanced Breast Cancer
Interventions
DRUG

AZD9833

AZD9833 taken orally

Trial Locations (3)

104-0045

Research Site, Chūōku

277-8577

Research Site, Kashiwa

135-8550

Research Site, Kōtoku

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY